Patrick Aisher

blu 2 bolle trasparenti.png

Patrick Aisher is a serial entrepreneur who has invested in the life science industry since 1997. He has focused on biomedical technology companies developing medical devices, biopharmaceuticals, and healthcare services in over 40 direct investments.

Mr. Aisher has a broad portfolio including various successful NASDAQ exits, two exits via trade sale at $40M (KB Medical to Globus in 2018) and $150M+ (Medina Medical to Medtronic in 2016) respectively, and two exits via international licensing transactions valued at $350M+.

He is a partner in a $200M venture fund for private innovative drug development companies, with a special emphasis on the next generation of biological drugs and drug formats. He is a Director of Aleva Neurotherapeutics SA, PreComb Therapeutics AG, and has identified and invested in early-stage spin-off opportunities from Universities in Barcelona, Zurich, Oxford, Boston, Stanford, NorthEastern, Texas, NYU, Lausanne and Geneva